Secretome Therapeutics
Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy
$30MSeries A
Role not disclosedRC
RA Capital Management
Activity from announced rounds
Activity in this selectionUnited States · May 31, 2026 · May 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $30M 1 disclosed · full round size, not this investor’s share